Cervical Cancer
Conditions
Interventions
2:DDP
Sponsors
Affiliated Hospital of Guizhou Medical University/Affiliated Cncer Hospital of Guizhou Medical University
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: ?The pathologically confirmed squamous cell carcinoma, adenocarcinoma and adenosquamous carcinoma after cervical biopsy before treatment; ? FIGO stage, cervical cancer patients with stage IB2, IIA2 and above stage IIB; ? All patients were not treated with radiotherapy, chemotherapy and surgery before chemoradiotherapy; ? Karnofsky score = 70 points; ? Age 18-65 years old; ? Normal bone marrow hematopoietic function (WBC>4.0×109/L, PLT=100×109/L, Hbt>70g/L); ? Liver function: alanine aminotransferase (ALAT), aspartate aminotransferase (AST) <1.5 times the upper limit of normal (ULN); total bilirubin <1.5×ULN; renal function: serum creatinine <1.5×ULN; ? Those who have no major organ dysfunction and no serious comorbidities, such as hypertension, diabetes, coronary heart disease and history of mental illness; ? Able to understand the study and signed the informed consent.
Exclusion criteria
Exclusion criteria: ?Small cell carcinoma, sarcoma, carcinosarcoma ?Have previously had invasive malignant tumor: non-malignant melanoma skin cancer is excluded; ? Systemic chemotherapy within the past 3 years ? Concurrently receiving chronic systemic immunotherapy or hormone therapy outside this study; previous history of pelvic or abdominal radiation therapy ? Pregnant women, lactating women
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| a.Efficacy evaluation (according to recist evaluation criteria) and toxicity immediately after treatment b. Progression-free survival (PFS) (time node: 3 years); | — |
Countries
China
Contacts
Public ContactLi Fenghu
Outcome results
None listed